A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
Table 2
Intragroup analysis of different outcome measures between baseline and week 12.
Measure
Olanzapine Baseline
Olanzapine Week 12
95% CI
Risperidone Baseline
Risperidone Week 12
95% CI
SAPS
63.61 ± 3.86
54.96 ± 3.42
9.187
0.0001
6.77, 10.53
62.19 ± 4.11
56.31 ± 3.02
6.315
0.0001
4.02, 7.74
SANS
46.26 ± 3.37
42.74 ± 3.69
3.858
0.0003
1.69, 5.35
46.83 ± 3.75
45.28 ± 3.06
1.754
0.08
−0.22, 3.32
CGI-S
3.65 ± 1.16
3.10 ± 1.03
1.942
0.05
−0.02, 1.12
3.25 ± 0.12
3.17 ± 0.16
2.191
0.03
0.01, 0.15
SAI
3.49 ± 0.61
3.83 ± 0.11
−3.004
0.003
−0.57, −0.11
3.51 ± 1.03
3.97 ± 0.74
−1.987
0.05
−0.92, 0.00
SAS
0.35 ± 0.76
0.38 ± 0.02
−0.216
0.82
−0.31, 0.25
0.36 ± 0.11
0.45 ± 0.19
−2.245
0.02
−0.17, −0.01
SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for Assessment of Negative Symptoms; CGI-S: Clinical Global Impressions-Severity Scale; SAI: Schedule for Assessment of Insight; and SAS: Simpson Angus Scale.
